Should I buy or sell Century Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IPSC shares. View IPSC analyst ratings or view top-rated stocks .

What is Century Therapeutics' stock price target for 2024?

5 Wall Street analysts have issued 12-month price targets for Century Therapeutics' stock. Their IPSC share price targets range from $5.00 to $24.00. On average, they expect the company's share price to reach $13.60 in the next twelve months. This suggests a possible upside of 340.1% from the stock's current price. View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts .

How have IPSC shares performed in 2024?

Century Therapeutics' stock was trading at $3.32 on January 1st, 2024. Since then, IPSC stock has decreased by 6.9% and is now trading at $3.09. View the best growth stocks for 2024 here .

When is Century Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IPSC earnings forecast .

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.07. The business earned $0.27 million during the quarter, compared to the consensus estimate of $1.69 million. Century Therapeutics had a negative trailing twelve-month return on equity of 54.73% and a negative net margin of 6,115.12%.

When did Century Therapeutics IPO?

Century Therapeutics (IPSC) raised $201 million in an initial public offering on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IPSC

Century Therapeutics (IPSC) Stock Price, News & Analysis

→ Chances are you know the firms on this list (From WealthPress) (Ad)

Free IPSC Stock Alerts

$3.09

+0.11 (+3.69%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.91
▼
$3.20
50-Day Range: $2.84
▼
$5.32
52-Week Range: $1.28
▼
$5.51

Volume: 112,750 shs
Average Volume: 133,410 shs
Market Capitalization: $200.29 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.60

Get Century Therapeutics alerts:

Century Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 340.1% Upside
$13.60 Price Target
Short Interest: Bearish
7.62% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.99
Based on 7 Articles This Week
Insider Trading: Selling Shares
$127,635 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.94) to ($2.00) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.19 out of 5 stars

Medical Sector

685th out of 911 stocks

Biological Products, Except Diagnostic Industry

114th out of 152 stocks

3.4

Analyst's Opinion

Consensus Rating
Century Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Century Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.62% of the float of Century Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Century Therapeutics has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in Century Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Century Therapeutics does not currently pay a dividend.
Dividend Growth
Century Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IPSC.

2.8

News and Social Media Coverage

News Sentiment
Century Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Century Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,635.00 in company stock.
Percentage Held by Insiders
Only 7.60% of the stock of Century Therapeutics is held by insiders.
Percentage Held by Institutions
50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Century Therapeutics are expected to decrease in the coming year, from ($1.94) to ($2.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Century Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Century Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Century Therapeutics has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Tranzact

What is Medicare Supplement Insurance?

Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you.

Learn More Here

About Century Therapeutics Stock (NASDAQ:IPSC)

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

IPSC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IPSC Stock News Headlines

April 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Century Therapeutics Amidst Strong Financial Backing and Promising Clinical Advances

April 15, 2024 | americanbankingnews.com

Analysts Issue Forecasts for Century Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:IPSC)

April 20, 2024 | TradingTips (Ad)

3 Sub-$10 Stocks to Buy for 2024

Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.

April 14, 2024 | uk.investing.com

Century Therapeutics shares target cut, retains Overweight

April 14, 2024 | americanbankingnews.com

Century Therapeutics (NASDAQ:IPSC) Stock Rating Reaffirmed by Piper Sandler

April 12, 2024 | msn.com

Century Therapeutics Gears Up to Conquer Highly Unmet Areas in Autoimmune Disease Treatments

April 12, 2024 | americanbankingnews.com

Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Average Rating of "Moderate Buy" from Analysts

April 12, 2024 | markets.businessinsider.com

Century Therapeutics: Hold Rating Justified Amid Strategic Acquisition and Ongoing Clinical Trials

April 20, 2024 | Tranzact (Ad)

What is Medicare Supplement Insurance?

April 11, 2024 | globenewswire.com

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

April 8, 2024 | globenewswire.com

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 29, 2024 | finance.yahoo.com

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

March 19, 2024 | markets.businessinsider.com

Strong Buy Rating for Century Therapeutics Amid Promising CNTY-101 Developments and Market Catalysts

March 19, 2024 | globenewswire.com

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Century Therapeutics on Strong Clinical and Financial Outlook

March 15, 2024 | finanznachrichten.de

Century Therapeutics, Inc.: Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

March 14, 2024 | investorplace.com

IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023

March 14, 2024 | benzinga.com

Century Therapeutics: Q4 Earnings Insights

March 14, 2024 | globenewswire.com

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

March 11, 2024 | msn.com

Century Therapeutics to Showcase Groundbreaking Cancer Research at AACR Annual Meeting 2024

March 9, 2024 | finance.yahoo.com

Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares

March 5, 2024 | globenewswire.com

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

February 22, 2024 | investorplace.com

3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024

February 15, 2024 | seekingalpha.com

IPSC Century Therapeutics, Inc.

February 14, 2024 | investing.com

Century Therapeutics Inc (IPSC)

February 1, 2024 | finance.yahoo.com

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 22, 2024 | benzinga.com

IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data

See More Headlines

Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:IPSC
CUSIP: N/A
CIK: 1850119
Web: www.centurytx.com
Phone: 267-817-5790
Fax: N/A
Employees: 152
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.60
High Stock Price Target: $24.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +340.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-136,670,000.00
Net Margins: -6,115.12%
Pretax Margin: -6,030.96%
Return on Equity: -54.73%
Return on Assets: -31.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.92
Quick Ratio: 9.92

Sales & Book Value

Annual Sales: $2.23 million
Price / Sales: 89.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.09 per share
Price / Book: 1.00

Miscellaneous

Outstanding Shares: 64,820,000
Free Float: 59,892,000
Market Cap: $200.29 million
Optionable: Optionable
Beta: 1.33

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Adrienne Farid Ph.D. (Age 62)
COO & Head of Early Development
Comp: $650.66k
Mr. Brent Pfeiffenberger M.B.A.
Pharm.D., CEO & Director
Mr. Douglas Carr CPA
Interim Principal Financial Officer, Senior VP of Finance & Operations and Secretary
Dr. Gregory Russotti Ph.D. (Age 57)
Chief Technology & Manufacturing Officer
Mr. Kenneth J. Dow J.D.
Senior VP of General Counsel
Dr. Shane Williams Ph.D.
Chief People Officer
Dr. Hyam I. Levitsky M.D. (Age 66)
President of Research & Development
Comp: $502.12k
Michael Naso Ph.D.
Senior VP of Cell Engineering
Dr. Nick Trede M.D.
Ph.D., Senior VP & Head of Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IPSC Stock Analysis - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IPSC shares.
View IPSC analyst ratings or view top-rated stocks.
What is Century Therapeutics' stock price target for 2024?: 5 Wall Street analysts have issued 12-month price targets for Century Therapeutics' stock. Their IPSC share price targets range from $5.00 to $24.00. On average, they expect the company's share price to reach $13.60 in the next twelve months. This suggests a possible upside of 340.1% from the stock's current price.
View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts.
How have IPSC shares performed in 2024?: Century Therapeutics' stock was trading at $3.32 on January 1st, 2024. Since then, IPSC stock has decreased by 6.9% and is now trading at $3.09.
View the best growth stocks for 2024 here.
When is Century Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IPSC earnings forecast.

How were Century Therapeutics' earnings last quarter?: Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.07. The business earned $0.27 million during the quarter, compared to the consensus estimate of $1.69 million. Century Therapeutics had a negative trailing twelve-month return on equity of 54.73% and a negative net margin of 6,115.12%.
When did Century Therapeutics IPO?: Century Therapeutics (IPSC) raised $201 million in an initial public offering on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.
How do I buy shares of Century Therapeutics?: Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IPSC) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial